My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

1.570 -0.050 (-3.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why BioXcel Therapeutics Stock Marched Higher Today ↗

May 08, 2023

The biotech's Q1 earnings report set the stage for a flurry of important clinical updates in the coming months.

Via The Motley Fool

BioXcel Earnings Miss Q1 Estimates Due To Higher Costs, Expects Uptick In Revenues ↗

May 08, 2023

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported first-quarter FY23 revenues of $206,000,

Via Benzinga

Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite. ↗

May 08, 2023

Axsome shares are nearing a breakout point. But BioXcel crumbled on its report.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 08, 2023

Via Benzinga

BioXcel Therapeutics's Earnings Outlook ↗

May 05, 2023

Via Benzinga

The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO ↗

May 04, 2023

This company is hoping to execute for a second time on its moonshot goal.

Via Investor's Business Daily

6 Analysts Have This to Say About BioXcel Therapeutics ↗

March 10, 2023

Via Benzinga

Earnings Preview: BioXcel Therapeutics ↗

March 08, 2023

Via Benzinga

Expert Ratings for BioXcel Therapeutics ↗

February 08, 2023

Via Benzinga

Why BioXCel Therapeutics Stock Jumped This Week ↗

December 15, 2022

A couple of analysts recently upgraded their views on the biotech stock.

Via The Motley Fool

Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 21, 2023

Morgan Stanley boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $447 to $466. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. HubSpot shares fell 1.9% to close at...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023 ↗

March 10, 2023

Via Benzinga

BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype ↗

February 14, 2023

Via Benzinga

Analyst Ratings for BioXcel Therapeutics ↗

December 01, 2022

Via Benzinga

Is This Soaring Growth Stock a Buy? ↗

November 20, 2022

The answer may depend on your risk tolerance.

Via The Motley Fool

Recap: BioXcel Therapeutics Q2 Earnings ↗

August 09, 2022

BioXcel Therapeutics (NASDAQ:BTAI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023 ↗

February 08, 2023

Via Benzinga

ChatGPT Is Just The 'Tip Of The Iceberg' In Content-Creating Artificial Intelligence; Get Ready For 'A Lot Of Disruption' (Not Just At Google) ↗

February 03, 2023

"A lot of disruption" may be coming soon to a host of industries. Google may be at risk.

Via Investor's Business Daily

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

2 Beaten-Down Stocks to Watch Closely Next Year ↗

December 06, 2022

These biotechs could skyrocket in 2023, but only if they can execute their plans.

Via The Motley Fool

BioXcel Therapeutics: Q1 Earnings Insights ↗

May 09, 2022

BioXcel Therapeutics (NASDAQ:BTAI) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why BioXcel Therapeutics Stock Triumphed This Week ↗

December 02, 2022

An analyst feels that the best is shortly to come for the company.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022 ↗

December 01, 2022

Via Benzinga

Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher' ↗

November 18, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."

Via Benzinga

Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday ↗

November 11, 2022

Gainers

Via Benzinga

Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday ↗

July 14, 2022

Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.

Via Benzinga

24 Stocks Moving in Thursday's Pre-Market Session ↗

June 02, 2022

Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗

July 07, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 25, 2022

Gainers

Via Benzinga

Preview: BioXcel Therapeutics's Earnings ↗

May 06, 2022

BioXcel Therapeutics (NASDAQ:BTAI) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that BioXcel...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.